PSA Screening Tied to 15-Year Prostate Cancer Death Rate

JAMA Network

About The Study: A single invitation for prostate-specific antigen (PSA) screening compared with standard practice without routine screening reduced prostate cancer deaths at a median follow-up of 15 years in this secondary analysis of a randomized clinical trial. However, the absolute reduction in deaths was small.

Authors: Richard M. Martin, B.M., B.S., Ph.D., of the University of Bristol in Bristol, United Kingdom, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jama.2024.4011)

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.